PD-1 (D4W2J) – 148Nd
Catalog: 714801 Clone: D4W2J Isotype: Rabbit IgG
Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store a 4°C
IHC: PD-1 staining of FFPE human tonsil
MIBI: PD-1 staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)
IHC: PD-1 staining of FFPE human liver
MIBI: PD-1 staining (cyan) of FFPE human liver, counterstained with dsDNA (magenta)
Background: PD-1 (programmed cell death protein 1, CD279) is expressed on activated T cells and binds to PD-L1 and PD-L2 to inhibit T cell activation through recruitment of phosphatases that attenuate TCR signaling. The interaction between PD-1 and PD-L1 supports tolerance to self-antigens and contributes to the healthy down-regulation of immune activation following viral clearance. In cancer the PD-1/PD-L1 interaction is exploited by tumor cells to dampen an immune response from tumor-infiltrating lymphocytes and as such these immune checkpoint molecules are being actively targeted by immuno-oncology therapies.
Validation: Each lot of conjugated antibody is quality control tested by MIBIscope™ analysis of stained tissue microarray using the appropriate positive and negative tissue field of views and are pathologist verified.
Recommended Usage: 1 uL per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application. Suggested starting range is 1:100.
- Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response
Biomarkers and Combinations. Science translational medicine. 2016; 8(328):328rv4.
* Conjugate tested on human tissue.